Last reviewed · How we verify
JAK-2 inhibitor
JAK-2 inhibitor is a Small molecule drug developed by Pi Research Consultancy Center, Bangladesh. It is currently in Phase 1 development. Also known as: Tofacitinib.
At a glance
| Generic name | JAK-2 inhibitor |
|---|---|
| Also known as | Tofacitinib |
| Sponsor | Pi Research Consultancy Center, Bangladesh |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms (PHASE1, PHASE2)
- A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) (PHASE1)
- Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (PHASE1, PHASE2)
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms (PHASE2)
- Pacritinib With Aza for Upfront Myelodysplastic Syndrome (PHASE1, PHASE2)
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (PHASE2)
- CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)
- Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JAK-2 inhibitor CI brief — competitive landscape report
- JAK-2 inhibitor updates RSS · CI watch RSS
- Pi Research Consultancy Center, Bangladesh portfolio CI
Frequently asked questions about JAK-2 inhibitor
What is JAK-2 inhibitor?
JAK-2 inhibitor is a Small molecule drug developed by Pi Research Consultancy Center, Bangladesh.
Who makes JAK-2 inhibitor?
JAK-2 inhibitor is developed by Pi Research Consultancy Center, Bangladesh (see full Pi Research Consultancy Center, Bangladesh pipeline at /company/pi-research-consultancy-center-bangladesh).
Is JAK-2 inhibitor also known as anything else?
JAK-2 inhibitor is also known as Tofacitinib.
What development phase is JAK-2 inhibitor in?
JAK-2 inhibitor is in Phase 1.
Related
- Manufacturer: Pi Research Consultancy Center, Bangladesh — full pipeline
- Also known as: Tofacitinib
- Compare: JAK-2 inhibitor vs similar drugs
- Pricing: JAK-2 inhibitor cost, discount & access